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ABSTRACT
The Saccharomyces cerevisiae general regulatory
factor CP1, a helix-loop-helix protein that binds the
centromere DNA element I (CDEI) of yeast centromeres,
is required in yeast for optimal centromere function and
for methionine prototrophy. Mutant alleles of CEP1, the
gene encoding CP1, were generated by linker insertion,
5'- and 3'-deletion, and random mutagenesis and
assayed for DNA binding activity and their ability to
confer CP1 function when expressed in yeast. A
heterologous CDEI-binding protein, TFEB, was also
tested for CP1 function. The results suggested that
DNA binding is required for both biological functions
of CP1 but is not sufficient. A direct and quantitative
correlation was observed between the chromosome
loss and nutritional (i.e., Met) phenotypes of strains
carrying loss of function alleles, but qualitatively the
chromosome loss phenotype was more sensitive to
decreased CP1 expression. The data are consistent
with a model in which CP1 performs the same general
chromatin-related function at centromeres and MET
gene promoters and is normally present in functional
excess.
INTRODUCTION
The Saccharomyces cerevisiae centromere-binding protein CP1,
encoded by the gene CEPJ (also designated CBFJ and CPFI),
is a member of the basic region-helix-loop-helix (b-HLH) family
of DNA binding proteins and is required in yeast for optimal
chromosome segregation and methionine prototrophy (1, 2, 3).
Its role in chromosome segregation is mediated through an
interaction with the conserved DNA element I (CDEI) found in
S. cerevisiae centromeres. This degenerate element, RTCACRTG
(R=purine), contains the consensus CANNTG motif recognized
by all known b-HLH DNA binding proteins. Strains harboring
cepl null mutations show increases in the frequency of mitotic
chromosome nondisjunction and in premature segregation of sister
chromatids during meiosis (4). The requirement for CP1 in
methionine metabolism appears to be exerted at the level of
transcription. Consensus CDEI sites are found in the promoter
regions of most methionine biosynthetic (MET) genes, and it has
been shown that cepl mutants fail to properly express MET16,
the gene encoding phosphoadenylylsulfate (PAPS) reductase (5).
CP1 does not appear to be a typical transactivator protein (e.g.,
GAL4, GCN4, PH04). Thomas et al. (5) found that LexA-CP1
fusion proteins fail to activate LexA DNA binding site-driven
reporter genes, suggesting that CP1 lacks inherent transcriptional
activation function. These authors proposed that CP1 binding at
MET gene promoters is required to allow binding of MET4, a
B-ZIP factor, which appears to be the direct transactivator of
MET gene transcription. The actual mechanism by which CPl
might carry out this facilitator function is not known, but Mellor
et al. (3) have shown that binding by CPl alters the chromatin
structure of ME725, GAL2, and TRP1 gene promoter regions,
all of which contain CDEI sites. Specifically, these regions are
less sensitive to digestion by micrococcal nuclease in strains that
lack CP1. One implication of these results is that CP1 mediates
increased accessibility of MET gene promoter regions to
interactions by other transcription factors (MET4?), presumably
by reorganizing the local chromatin structure (5). At centromeres,
CP1 may act similarly to facilitate the binding of other
kinetochore proteins such as the CDEIH-associated motor protein
CBF3 (6, 7).
CPl has been grouped with RAP1, REB1, and ABF1, proteins
which comprise a family of S. cerevisiae factors known as general
regulatory factors (GRF's) (8, 9, 10, 11, 12). All of these factors
are relatively abundant, sequence-specific DNA binding proteins
that have many genomic sites of interaction and are involved in
diverse chromosomal functions. In addition to having both
positive and negative effects on gene transcription, GRF's have
been shown to be associated with chromosomal origins of
replication (ABF1), telomeres (RAPI), and centromeres (CP1).
REB1 (also known as factor Y or GRF2) is a strong positioner
of nucleosomes (13).
Considerable evidence suggests that specific DNA binding is
required for CP1 function. The equivalent and nonadditive effect
of cis and trans CDEI/cepl mutations on mitotic centromere
function indicates that CP1 interacts at centromeric CDEI sites
(1) in carrying out its kdnetochore-related function. Domain swap
experiments strongly suggest that direct DNA binding is also
essential for the transcription function of CP1. Dang et al. (14)
have engineered a hybrid CP1 protein in which the basic region
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of the CP1 b-HLH domain is replaced by that of the mammalian
b-HLH protein AP4. The resulting mutant, CPl-AP4 has the
DNA binding specificity of AP4 (CAGCTG), is unable to bind
CDEI sites (CACGTG), and does not confer methionine
prototrophy when expressed in yeast. When Met+ revertants of
CP1-AP4 are selected, all contain an amino acid change in the
basic region (amino acid 235) that also reverts the binding
specificity to CACGTG. A seemingly contradictory result has
been obtained by Mellor et al. who have isolated a CPl mutant
which apparently fails to bind DNA yet confers methionine
prototrophy (15). They have concluded that direct DNA binding
is required only for the centromere function of CP1 and not the
transcription function.
The present study was undertaken as an attempt to resolve the
discrepant findings concerning CP1 DNA binding and biological
function. In vitro-constructed cepl mutants were generated,
introduced into cepl null strains of yeast, and tested for function.
The DNA binding affinities and expression levels of the mutant
gene products were determined in order to establish quantitative
correlations between binding and function. A second objective
of the study was to determine if specific DNA binding alone is
sufficient for CPI function. For this, we analyzed the ability of
a heterologous CDEI-binding protein to rescue CP1 function in
yeast. The results were most consistent with the view that direct
DNA binding is essential but not sufficient for both kinetochore
and transcription functions of CP1 and that CP1 is normally
present in functional excess.
MATERIALS AND METHODS
Strains and media
Strains SMAF13cx [MA Ta cryl his4-580 lys2 trpl SUP4-3 ade2-1
leu2 ura3-52 ade3 cepl::URA3-11 smal-F13 (pho8O)] and
R31-1A [MA4Ta leu2A1 lys2-801 trplAl ura3-52 ade2-101
his3A200 CFVII(RAD2.d.URA3 SUPl 1)] have been described
(16). Strain R31-3B is identical to R31-1A except that it also
carries the cepl::TRPJ gene disruption allele (16). All media were
as described (4). Yeast transformations were performed using
the lithium acetate procedure as modified by Schiestl (17).
CEPI expression vectors and mutant alleles
Figure 1 shows the two basic vectors used for expressing CP1.
Plasmid pDR28ARS contains, in addition to ARS1, CEN3, and
the selectable marker LEU2, an epitope-tagged CEPI gene
(CEP1 FIG). CEPI FAG differs from wild-type CEPI in that
codons 1-8 were changed to encode MDYKDDDD which
specifies the FLAGTm epitope developed by Immunex
Corporation (Seattle) (18). The HindEI site encoded at codons
9/10 of wild-type CEPI is retained in the same reading frame
in CEPI FIAG. The E.coli T7 expression vector pJH7 was
derived from pET-3d (19) by destroying the XbaI and HindI
sites, ligating an XbaI nonsense linker (encoding translation stops
in all three reading frames) to the BamHI site, and inserting
CEPIFf4G. Yeast multicopy (YEp) constructs were obtained by
subcloning CEPI BamHI-BglII fragments (from pDR28ARS
and derivatives) into the BamHI site of the yeast 21-LEU2 vector
YEp351 (20); all plasmids have the CEPI segments in the same
relative orientation.
The LI-301 allele was constructed by limited PstI digestion
ofpDR28ARS, removal of the 3' overhanging ends using Klenow
enzyme in the absence of dNTP's, and religation in the presence
of 10-bp synthetic XhoI linkers (5'-CCCTCGAGGG-3'). Alleles
BamHI
Figure 1. Plasmids used for expression of CEPI alleles in yeast (pDR28ARS)
and E.coli (pJH7).
LI-381PG and LI-381SR were constructed by digesting
pDR28ARS with MMuI, filling in the staggered ends with Klenow
polymerase, and ligating in the presence of either 8 bp SmaI
linkers (5'-GCCCGGGC-3') or 8 bp XhoI linkers (5'-CCTCG-
AGG-3'), respectively. The LI-259 allele was derived from the
primary CEPI clone pDR4-2 (1) by partial SspI digestion and
ligation in the presence of 12-bp SacdI linkers (5'-TCCCCGC-
GGGGA-3'). One of the ligation products contained a single
linker inserted at codon 259. The HindJII-BgllI fragment of this
plasmid was then used to replace that of pDR28ARS. DNA
sequencing was performed on all of the mutant constructs to
verify that the linkers had inserted as expected and the CEPI
reading frame was preserved.
The R235H point mutant was obtained by hydroxylamine
mutagenesis of pDR28ARS in vitro and screening for a Met-
phenotype by plasmid shuffling (21, 22). One mutant plasmid
contained two point mutations, a G to A transition at nucleotide
position 959, and a G to T transversion at position 1175
(nucleotide coordinates of reference (1)). The mutations were
separated by subcloning HindIHl-PstI and PstI-BgII fragments
of pHA4 into pDR28ARS. The mutation at position 1175 was
silent, but the mutation at position 959 (R235H) resulted in loss
of CPI function.
The 5' deletions were made by exonuclease III digestion of
HindI-cut pDR4-2 using Erase-a-Base kit components
(Promega) following the manufacturers instructions. After
addition of HindI linkers (GAAGCTTC), the DNA was cleaved
with Bglll and fragments ligated to HindII-BglIl digested
pDR28ARS. Deletion endpoints were determined by DNA
sequencing. The 3' deletion allele, CA302, was obtained in a
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similar fashion except exonuclease digestion was initiated at the
BglII site, 14-bp XbaI nonsense linkers (having stop codons in
all reading frames) were added, and the resulting HindIll-XbaI
fragment was initially ligated to HindlI-XbaI-cut pJH7.
Subsequently, the CA302 segment was removed as a
HindRI-BamHI fragment and ligated to HindIll-BgllI cut
pDR28ARS for expression in yeast. This plasmid transformed
yeast poorly, possibly because the CEPI transcription unit directly
abutted the ARS1 sequence. The problem was alleviated when
0.6 kbp of CEPI downstream sequence (along with 19 C-terminal
codons of CP1) were reintroduced. The resultant construct,
pJHl 1, is effectively -an internal deletion of CEP1 codons
303 -332, but translation terminates at codon 302 due to the XbaI
nonsense linker at the deletion endpoint.
TFEB expression plasmids all contain nucleotides 871 (RsaI)
to 1523 (SmaI) of the TFEB cDNA isolated by Carr and Sharp
(23). Using standard procedures, an 8-bp HindHI linker was
added at the 5'-end and a 14-bp XbaI nonsense linker added at
the 3'-end. This segment was then inserted into pJH7 for E. coli
expression and into the pJHll vector backbone for expression
in yeast.
Assays of cepi phenotypes
Mitotic chromosome loss rates were measured by fluctuation
analysis as described (24) except that leucine was omitted from
all media to maintain selection for the CEPJ-containing plasmids.
The tester strain (R3 1-3B) carried the nonessential chromosome
fragment CFVII(RAD2.d. URA3 SUPJJ) whose rate of loss was
measured. A semi-quantitative assay was devised to score
methionine-independent growth. Several independent
transformant colonies of each strain were grown as patches of
cells at 30°C on plates lacking leucine, then replica plated in
triplicate onto -Leu dropout and -Leu -Met double dropout
plates. The plates were incubated at 22°C, 30°C, and 34°C and
scored after 24, 48, and 72 hours. On each day, the patches were
assigned a score of 2 (confluent growth), 1 (less than confluent
growth) or 0 (no detectable growth), and the individual scores
added after 3 days. Thus, the maximum score is 6 and the
minimum 0. Wild-type cells routinely give a score of 6 and cepl
mutants a score of 0.
Preparation of yeast and E.coli extracts
Yeast strains (R31-3B) carrying CP1 expression plasmids were
grown at 30°C in 100 ml of selective (-Leu) medium to mid
log phase. All subsequent manipulations were carried out on ice
or in a 4°C cold room. The cells were washed once with water,
resuspended in two pellet volumes of 200 mM Tris (pH8. 1)-10
mM MgCl2-10 mM ,B-mercaptoethanol-10% glycerol-i mM
PMSF, transferred to 2-ml screw cap microfuge tubes containing
1 ml of 0.5-mm glass beads, and broken by two-20 s bursts in
a Biospec Products Mini-Bead Beater. Tubes were cooled for
20 s in an ice-ethanol bath between agitations. Lysates were
transferred to 1.6-ml tubes and spun in a microcentrifuge for 10
min to remove cellular debris. Supernatants were frozen in
aliquots on dry ice and thawed only once before use. Protein
concentrations were determined by the method of Bradford using
bovine serum albumin as standard (25).
Soluble E. coli extracts were prepared essentially as described
by Studier et. al. (19). The host strain for T7-induced expression
was BL21(DE3) carrying the plasmid pLysS. BL21(DE3)
transformants carrying pJH7-derived CP1 expression plasmids
and chloramphenicol. The overnight cultures were diluted 1:100
into fresh medium and grown at 37°C to an OD6M of 0.3-0.6
at which time isopropylthiogalactoside (IPTG) was added to a
final concentration of 0.4 mM. Incubation was continued for an
additional 90 min. Cells were pelleted, resuspended in extract
buffer [200 mM Tris (pH8.1), 10 mM MgCl2, 10 mM (3-
mercaptoethanol, 10% glycerol, 0.5 mM PMSF, 0.5 mM DTT,
0.2% NP40] to a final concentration of 4 OD6W units per ml,
and chilled on ice. Cell breakage was accomplished by sonication
using a Branson J-17A sonicator at full power for two 30 s bursts
with a 30 s rest on ice between disruptions. After pelleting cellular
debris by centrifugation for 10 min at 4°C in a microcentrifuge,
the supernatants were transferred to clean tubes and frozen on
dry ice.
DNA binding assays
Probe for DNA binding assays was prepared from plasmid
pDRl-7 which contains a single copy of the CDEI oligonucleotide
5'-GATCCAAATAAGTCACATGATGATA(GATC)-3' cloned
into the BamHI site of pUC18. After EcoRI/HindlI digestion
and Klenow fill-in using [a-32P]dATP, the 72-bp probe was
isolated by polyacrylamide gel electrophoresis and electro-elution.
Probe DNA concentration was determined using a Hoeffer
Scientific model TKO 100 DNA fluorimeter. Alternatively or
in addition, samples of probe DNA were run on a 6%
polyacrylamide gel along with known amounts of EcoRI-HindIH
digested pDR1-7 plasmid DNA and DNA concentration
determined after ethidium bromide staining (26).
Gel shift DNA binding assays were performed as described
(27). Binding reactions contained (in 15 1l) 20 mM Hepes, 150
mM KCl, 5 mM MgCl2, 2.5% glycerol, 0.25 mg/ml bovine
serum albumin, 0.05% Nonidet P40, 20,000 cpm Of 32p-
labeled probe DNA (200-500 pg), unlabeled competitor DNA,
and either yeast or E. coli extract. E. coli extract assays used 1
yd of a 1: 100-diluted extract (30-60 ng total protein) and 2 /Ag
of poly d(I-C) as unlabeled competitor. Yeast extract assays used
20 ,.tg total yeast protein (2-5 ,ul extract) and either 2.5 jig
pDR1-12 plasmid DNA (specific competitor) or 2.5 jig pDR2-14
plasmid DNA (nonspecific competitor). The specific competitor
DNA was plasmid pDRI-12 which contains a pentamer of the
CDEI oligo described above in the BamHI site of pUC18. The
amount used (2.5 ,tg/reaction) provided a 500- to 1300-fold molar
excess of CDEI sites relative to the labeled probe. Nonspecific
competitor was plasmid pDR2-14 which is identical to pDRl-12
except that it contains a pentamer of an unrelated oligonucleotide.
Determination of relative apparent binding affinities
Relative apparent binding affmiities were determined by
quantitative gel shift DNA binding assays ofE.coli-produced gene
products. To quantitate the amount of binding protein in each
extract, equal volumes of extract were run on 12% SDS
polyacrlyamide (Laemmli) gels and the gels stained with
Coomassie blue. The CP1 bands were clearly detectable above
the background of E. coli proteins. After destaining, the gels were
sandwiched between two sheets of 3M transparency film and
scanned using a Hoeffer Scientific GS-300 Densitometer. Peak
integration was accomplished using GS-365 PS Electrophoresis
Data System software (Hoeffer). Gel lanes of extracts of E. coli
not carrying CPl expression plasmids were scanned to determine
background staining in the regions of the gels containing CP1
products. This background accounted for less than 10% of the
integrated CP1 signal in all cases except for LI-318SR whichwere grown ovemight at 37 0C in LB broth containing ampicillin
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was poorly expressed. Background-subtracted CP1 integration
values were corrected for differing polypeptide molecular weight
and then normalized to the CP1 signal obtained from a single
extract of the NA208 mutant, an aliquot of which was included
on all gels for standardization. Four separate scans of samples
from at least two independent extracts were carried out for each
CP1 protein. Results from duplicate scans differed by less than
10%.
The absolute concentration of CP1 in the extracts was esfimated
by running the 'standard' NA208 extract on a gel along with
known amounts of homogeneously pure human serum albumin
(a gift of R. Feldhoff, University of Louisville School of
Medicine). After densitometric analysis as described above, the
concentration of NA208 polypeptide was determined from a
standard curve. The 'standard' extract contained 0.47 mg/mi of
NA208 polypeptide (29 ,uM).
After performing gel shift DNA binding assays as described
above, dried gels were analyzed on a Betagen Betascope 603 blot
analyzer to quantitate the amount ofbound and free probe in each
binding reaction. Relative apparent CP1 binding constants (Krel)
were calculated using the following equation:
Kest RRtest [CPl]ref
Krel = = * (1)
Kref Rref [CP]test
Kte and Kref are the apparent binding constants of, respectively,
the test and reference proteins; Rtest and Rrf are the ratios of
bound to free probe for the respective binding reactions;
[CPltSt] and [CPlref] are the total concentration of test and
reference proteins in the reactions, respectively. The standard
NA208 extract was used as the 'reference' in all cases. Equation
1 assumes that the concentration of unbound CPl protein in each
binding reaction is approximately equal to the input concentration
of CP1, i.e., conditions of protein excess. This condition was
met in our reactions where the total CP1 concentration was
10-20 nM and the concentration of bound probe was 0.01 -0.15
nM. The reported results (Table 1) are the means of
determinations for two or three independent extracts of each
protein. The average deviation from the mean was less than 20%.
Immunodetection of FLAGged CP1 proteins
Crude yeast proteins (up to 30 ,ug of total protein) were resolved
on 12% polyacrylamide SDS (Laemmli) minigels (0.75 mm).
Proteins were transferred to Immobilon PVDF membranes
(Millipore) in 1 xCAPS buffer containing 10% methanol (28).
Detection of FLAGged proteins was carried out using the
Amersham ECL detection system following the manufacturers
guidelines. The primary antibody used was monoclonal anti-
FLAG-M5 mouse IgGl diluted to 10 mg/ml in 0.1%TTBS
[0.1 %Tween-20, 20mM Tris-HCI (pH7.5), 0.5 M NaClI]. The
secondary antibody was peroxidase-conjugated goat anti-mouse
Ig (Boehringer Mannheim Biochemicals) diluted 1:3,000 in
0.1%TTBS containing 2.5% dry milk. After reaction with
antibody, membranes were washed three times in
0.1%TTBS-0.1% dry milk.
RESULTS
cepl mutations and phenotype analysis
The cepl mutants chosen for the first phase of this study are
diagrammed schematically in Figure 2. Mutations CA302,
LI-301, LI-318PG, and LI-318SR disrupt the C-terminal region
of CP1. It was known from preliminary experiments that these
mutations reduced but did not abolish specific DNA binding and
might therefore be useful for correlating binding and function.
For comparison, two non-DNA binding mutants were also
analyzed: mutation LI-259 is a four codon insertion into helix
2 of the b-HLH domain; mutation R235H is a point mutation
in the basic region. The last allele shown in Figure 2 was derived
from a cDNA clone of the mammalian b-HLH protein TFEB
(23). This factor, which has a binding specificity very similar
to CP1 (23), was tested to determine if a heterologous CDEI-
binding protein would confer CPL function in yeast. For positive
controls we used both wild-type CEPI as well as the N-terminal
truncation mutant NA208 (Figure 6), which was known to have
wild-type function (3). All of the alleles encoded an epitope tag
(FLAG) at the protein N-terminus but retained native CEPJ
promoter and translation initiation sequences. Substituting the
eight amino acid FLAG for the natural CP1 N-terminus leads
to no measurable alteration in CPl function (data not shown).
Table 1. Phenotypes conferred by cepi mutant alleles
Allele Met Phenotype CFVII Loss Ratea CDEI Bindingc
YCp YEp Absoluteb Relative
WT 6 6 3.0 x 10-4 1.0 1.0
NA333d (300) 0 0 1.2x10-2 40
NA333 (220) 0 0 1.2x10-2 37 <0.002
NA208 6 6 1.4x10-4 0.5 0.5
CA302 0 0 1.1x 10-2 37 0.016
LI-301 0 0 9.3 x 10-3 31 0.024
LI-318PG (300) 1 6 5.Ox 10-3 17
LI-318PG (220) 3 6 6.2x 10-3 21 0.13
LI-318SR 6 6 3.2x10-4 1.1 0.14
LI-259 0 0 1.0x10-2 33 <0.002
R235H 0 0 9.3 x 10-3 31 < 0.002
TFEB 0 0 9.0 x 10-3 30 0.5
aDetermined by fluctuation analysis using YCp transformants.
bLoss events/cell/division.
cRelative apparent binding affinities determined using E.coli-produced proteins (see Materials and Methods) and expressed as nonnalized values.
dNA333 lacks all but 17 C-terminal CP1 codons (Figure 6) and is used as the negative control.
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Before testing function in yeast, the mutant cepl alleles were
expressed in E.coli to obtain accurate estimates of the relative
apparent CDEI-binding affinities of the gene products. The
apparent affinities varied over a wide range (Table 1). The NA208
and TFEB gene products bound with an apparent affinity only
2-fold lower than that of wild-type CP1. In contrast, the R235H
and LI-259 gene products, both altered in the CP1 b-HLH
domain, possessed no detectable CDEI-binding activity. The C-
tenninal domain mutants had significantly reduced but measurable
DNA binding activities: the LI-318 mutations resulted in about
a 9-fold reduction in apparent binding affinity; while the LI-301
and CA302 mutations reduced apparent binding affinity 40- and
60-fold, respectively.
Next, the alleles were introduced into cepl null yeast strains
on both single- and multicopy plasmids and tested for expression.
An indirect test of expression was made by measuring CDEI-
binding activity present in crude extracts (Figure 3). Equal
amounts of crude yeast protein were used for the assays;
therefore, the amount of specifically bound probe depends both
upon binding affmity and upon the relative concentration of
binding protein in the extract. For the most part, the activities
HindIII
wr I
9
u5 - z j
Comp. DNA: + - + - + - + - + -
cPnDNA 0_
..:
14
re
enIA, OC? T In en
-J-J
Comp. DNA: + - + - + - + - + - +
CP1.DNA -_ @ ? w
SspI PstI MIUlII I
29 301 318
H-
Figure 3. DNA binding activity of yeast transformants carrying mutant cepi
alleles. Gel shift DNA binding assays of crude extracts were carried out as
described in Materials and Methods. The addition of specific (+) or nonspecific
(-) unlabeled competitor is indicated. The various mutations are described in
Figures 2 and 6. The YEp351 transformant carries the expression vector (LEU2)
without a CPl insert. The assay shown utilized extracts prepared from cepl
transformants carrying the mutant alleles on multicopy (YEp351-derived) plasmids.
The same relative results were obtained when extracts were prepared from
transfonmants carrying single-copy plasmids, but the absolute levels of CDEI-
binding activity were less (not shown).
ASRR
Figure 2. CEPI mutant alleles. Alleles were constructed as described in Materials
and Methods. Numbers below the diagrams indicate codon positions. The 3'
deletion, CA302, is actually an internal deletion (codons 302-332) terminated
by an XbaI nonsense linker (cross hatched box) after codon 301. LI-301 is a
linker insertion at the PstI site which replaces amino acids 302 and 303 (LQ)
with those indicated. The remaining linker insertions contain in-frame insertions
of four codons immediatly 3' to the codon positions indicated. R235H is a histidine
to arginine substitution at position 235 (basic region). The TFEB allele expresses
the DNA binding domain of the mammian factor TFEB (23). The approximate
positions of the heterologous b-HLH domain and the leucine zipper (ZIP) ofTFEB
are indicated.
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Figure 4. Immunodetection of epitope-tagged proteins. Immunoblotting (see
Materials and Methods) was carried out using the same crude yeast extracts that
were used for the binding assay shown in Figure 3. Thirty ,ug of total protein
were were loaded except for extracts of strains carrying Ll-259 and R235H where
only 5 1xg were loaded and strain R19-4 where 80 /Ag was used. R19-4 carries
a chromosomal copy of CEPI FLAG. The two left-hand lanes contain
approximately 1 ng of E.coli-produced CP1 (pJH7) loaded alone (lane 2) or mixed
with control (YEp351) yeast extract (ane 1). The gel was intentionally overloaded
and the blot overexposed to maximize sensitivity. (Notice the absence of
background bands in the R235H and LI-259 lanes where less total protein was
loaded.)
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observed corresponded to those that would be expected from the
measured relative binding affinities of the respective gene
products: wild-type activity was observed for NA208 and TFEB;
reduced binding was observed for LI-318SR and LI-318PG; and
no binding was detected for R235H and LI-259. In all cases where
binding was observed, it was specific, as binding to the probe
was reduced in the presence of excess unlabeled CDEI site-
containing DNA. The binding activities observed for LI-301 and
CA302 were not in line with expectations. Given the 50-fold-
reduced binding affinity of these mutant gene products, LI-301
and CA302 transformants were expected to yield extracts with
extremely low (or undetectable activity). No detectable binding
was observed for CA302, but nearly wild-type activity was
observed for LI-301.
hnmunoblot analysis of the extracts (Figure 4) provided a direct
estimate of mutant gene expression and resolved the discrepancy
with respect to LI-301 and CA302. The LI-301 gene product,
as well as those of R235H and LI-259, were expressed at greater
than wild-type levels. The high relative concentration of LI-301
protein probably explains why appreciable CDEI-binding activity
was detected in LI-301 extracts despite the reduced binding
affinity. A gene product was not detected for CA302. Apparently
CA302 protein is not stable in yeast (although it is stable in
E. coli), making this mutant uninformative. Interestingly, the
LI-318PG product was also not detected, even though CDEI-
binding activity was present in the extract. Evidently, the DNA
binding assays were more sensitive at detecting CPl than
immunoblotting, and the concentration of CP1 product in the
LI-318PG extract lay between the detection limits of the two
assays. In any event, this result suggested that the steady-state
level of LI-318PG gene product was less than that of LI-318SR
and that the apparent difference in DNA binding activity in these
two extracts (Figure 3) was real. The NA208, TFEB, and
LI-318SR gene products were detected at levels comparable to
wild-type CP1.
The results of CP1 functional assays are reported in Table 1.
With two exceptions, CP1 function with respect to both
methionine biosynthesis and mitotic chromosome segregation
correlated with the presence or absence of CDEI-binding activity.
The nonbinding mutants R235H and LI-259 lacked any
measurable CP1 function. The NA208 and LI-318SR gene
products conferred wild-type function. The LI-318PG allele did
not confer full function when present on a single-copy (YCp)
plasmid; however, the Met phenotype was partially corrected at
reduced temperature (22°C), and both phenotypes were rescued
to wild-type (Met) or near wild-type (CF loss) levels when
LI-318PG was expressed from a multicopy (YEp) plasmid.
[Mitotic CF loss rate was rescued to 8.3 x lo-4 events/division.]
The temperature sensitivity and dosage dependence of the
LI-318PG phenotype suggested that the primary defect was in
expression, possibly due to protein instability, rather than a
specific deficiency in function. The reduced level of binding
activity and immunoreactive protein relative to LI-318SR (Figures
3 and 4) corroborate this conclusion. Despite having wild-type
CP1 function, multicopy plasmid transformants of LI-318SR and
LI-318PG expressed much lower than wild-type levels of CDEI-
binding activity (Figure 3), suggesting that CP1 is normally
present in significant excess.
The exceptions to the correlation between CDEI-binding
activity and CP1 function were TFEB and LI-301. The TFEB
gene product, which was expressed at levels similar to and had
an apparent CDEI-binding affinity only 2-fold lower than wild-
-Leu
YEp
-Leu, -Met
LI-301
WT
TFEB
LI-259
R235H
YEp351
LI-301
WT
TFEB
YEP LI-259
R235H
YEp351 L
WT
YCp? LI-301TFEB r
YEp35I
CEP1
ceplsmal
cepl smal
FSgure 5. Dominant negative effects of cepi mutant alleles. Transfonnants canying
the indicated alleles on single- (YCp) or multicopy (YEp) plasmids were grown
to mid log phase in medium lacking leucine (to select for the expression plasmid),
centrifuged, and diluted to a final concentration of 2 x 106 cells per ml in medium
lacking both leucine and methionine. For each strain, a series of five, 5-fold serial
dilutions were prepared in the double selection medium and 5 I1 aliquots were
spotted onto single selection (-Leu) and double selection (-Leu -Met) plates.
Plates were incubated at 30°C and photographed after 48 (CEPI) or 72 hours
(cepi snial). The YEp351 transformant carries the expression vector (LEU2)
lacking a CPI insert.
type CP1, exhibited no detectable cepl-complementing activity
under any condition tested. Likewise, LI-301 was totally inactive
in rescuing CP1 function, even though multicopy expression
resulted in almost wild-type levels of CDEI-binding activity in
crude extracts.
Dominant negative effects
The finding that TFEB and LI-301 transformants expressed wild-
type levels of CDEI-binding activity but were devoid of CPI
function strongly implied that CDEI-binding activity per se is
not sufficient to confer CPI function. But do TFEB and LI-301
gene products actually interact with CDEI sites in vivo? If so,
these mutants should display dominant negative phenotypes, i.e.,
they should inhibit the function of wild-type CP1 by
nonproductively occupying CDEI sites. When tested, none of
the mutants conferred a trans dominant phenotype in a CEPI +
host; however, TFEB and LI-301 did exhibit dominant negative
Met phenotypes when expressed in a cepl pho8O strain
background.
Mutations inpho8O suppress cepl methionine auxotrophy (16).
The suppression appears to be due to a direct activation of
methionine biosynthetic genes by the positive transcription factor
PHO4, which shares binding specificity with CP1 (14, 29). The
PHO4 activation pathway is not available under normal
conditions, because PHO4 is kept inactive by the negative
regulator PHO80 (30, 31). Mutations in p/w8O free PHO4 to
act constitutively, and cepl pho8O double mutants are
phenotypically Met+ (16). The test for dominant negative Met
phenotypes in the cepl pho8O (smal) background is shown in
Figure 5 (lower panels). [The smal (suppressor of cepl
methionine auxotrophy) complementation group is allelic to
pho8O.] When carried on either single- or multicopy vectors,
LI-301 and TFEB caused dramatic reductions in the ability of
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Figure 6. cepi frame-shift alleles and their ability to complement cepl phenotypes. The fusion joint at the deletion endpoint is shown above each diagram. HindI
linker sequences are in lower case, FLAG and CEP1 sequences in upper case. The naturally occurring Hindu site spanning codons 9/10 in the wild type allele
(WT) is underlined. Nucleotides are grouped as triplets to indicate the reading frame established by the ATG initiator codon provided by the expression vector.
Underlined triplets indicate the correct CP1 reading frame with the numbers in parentheses indicating the net shift in reading frame relative to the initiating ATG
(and FLAG). The alleles are named to indicate the native CEPI codon at the fusion site. Methionine phenotype and CFVII loss rates were determined as described
in Materials and Methods. Absolute loss rates are loss events/cell/division.
the respective strains to grow in the absence of methionine. The
non-DNA binding mutants R235H and LI-259 had no negative
effects on the growth of the cepl smal strain in the absence of
methionine (neither do they exhibit negative phenotypes in a
CEP1+ background; Figure 5, top). The inhibitory effects of
TFEB and LI-301 were not due to a direct inactivation of PHO4,
because PHOS expression in the cepl snial transformants was
unaffected (not shown). [PHO5, encoding repressible acid
phosphatase (rAPase), is a downstream target of PHO4 (31).]
That expression of TFEB and LI-301 inhibits suppression by
PHO4 implies that both TFEB and LI-301 gene products enter
the nucleus and occupy CDEI sites.
CEPI frame-shift mutants
In constructing N-terminal truncation mutants of CP1, a number
of constructs were generated which did not maintain translational
reading frame, i.e., CEPJ coding sequences were out of frame
relative to the initiator ATG codon of the expression vector (see
Materials and Methods). To our surprise, several such frame-
shifted constructs were found to confer a partial Met+
phenotype. Apparently, low levels of truncated but functional
CP1 gene product were produced either by frame-shift
suppression or translational (re)initiation at alternative ATG
codons. While the exact mechanism of expression was not known,
preliminary characterization of the mutants indicated a wide range
of activities, providing us the opportunity to systematically
compare Met and chromosome loss phenotypes under conditions
of limiting CP1 expression.
The frame-shift alleles and their ability to rescue cepl
phenotpes are shown in Figure 6. The CEPI open reading frame
contains in-frame methionine codons at amino acid positions 153
CDEI Competitor.
0go
z
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Figure 7. CDEI binding activity of strains expressing cepl frame-shift alleles.
Binding assays were carried out as described in Materials and Methods. The crude
extracts were prepared from RB31-3B transformants carrying the mutant alleles
on single-copy (YCp) plasmids. Specific (+) or non-specific (-) plasmid
competitor DNA (2.5 Asg) was included in each reaction.
and 168. With the exception of NA86, the shorter the distance
between the deletion endpoint and the nearest in-frame ATG
(codon 153 for NA33, NA86, and NA137; codon 168 for
NA162), the better the allele at complementing cepi defects.
NA86 differs in that it is the best at complementing cepl defects
and that its CP1 coding sequences lie in the +2 reading frame
relative to the initiator ATG and FLAG codons (the other frame-
shift alleles lie in the +3 reading frame). The FLAG codons
contain three tandem ATG's in the +2 reading frame, one of
which may serve as the initiator for NA86. Most importantly,
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the results in Figure 6 show a direct and quantitative correlation
between the ability of an allele to promote methionine-independent
growth and its ability to rescue the cepl mitotic chromosome
loss defect.
To determine if the correlation between DNA binding activity
and biological function also held for these frame-shift mutants,
extracts of transformants carrying the frame-shift alleles were
assayed for CDEI-binding activity. As shown in Figure 7, the
only extracts in which specific CDEI binding activity was detected
were those of strains carrying the wild-type, NA208, and NA86
alleles. These three alleles were also the best at complementing
cepl phenotypes. The NA208 extract had wild-type binding
activity, while an equal amount of NA86 extract protein bound
markedly less probe, consistent with a reduced expression of this
allele due to the frame-shift mutation. The NA86 complex was
of a size consistent with it being initiated from an ATG very near
the fusion site (i.e., within FLAG). No CDEI-specific binding
activity was detected in extracts prepared from transformants
carrying the other out-of-frame alleles, consistent with their
reduced abilities to rescue cepl phenotypes. The apparent lack
of binding activity in NA33, NA137, and NA162 extracts
probably reflects the detection limit of the assay. There is no
reason a priori to assume that these gene products would lack
CDEI-binding activity. In-frame truncation alleles NA80, NA182,
and NA192 (as well as NA208) all produce wild-tpe levels of
CDEI-binding activity when expressed from single-copy plasmids
(data not shown). Evidently, extremely low levels of CP1
expression suffice for at least partial CP1 function.
DISCUSSION
As mentioned in the Introduction, a preponderance of evidence
indicates that direct and specific DNA binding is required for
CP1 biological function. Our results fully support that view. With
the exception of mutants which bind DNA but are nonfunctional
(LI-301, TFEB), the ability of mutant alleles to rescue both cepl
phenotypes correlates with the expression of CDEI-binding
activity. Nonbinding mutants (R235H, LI-259) have no detectable
function; mutants expressing wild-type (NA208) or reduced
binding activity (LI-318SR, multicopy LI-318PG) display wild-
tpe function; those expressing very low (NA86) or undetectable
(NA162, NA137, and NA33) binding activity have impaired
function. The lack of observed activity in the case of the latter
three frame-shift mutants probably reflects assay insensitivity,
since there is no reason a priori to predict that the gene products
intrinsically lack DNA binding activity. None of the mutations
separated the segregation and transcription functions of CP1.
While certain mutants restored methionine prototrophy without
completely rescuing the chromosome loss defect (Met+Chl-),
no mutations causing the reverse phenotype (Met-Chl+) were
obtained. In all cases, mutations that had any measurable
phenotypic effect invariably affected both functions, and for the
N-terminal truncation/frame-shift series, a direct and quantitative
correlation was observed in the degree to which Chl and Met
phenotypes were complemented. Given the limited number of
mutations in hand, we are wary of overinterpreting this result,
but the data are consistent with CP1 performing a similar function
at MET gene promoters and centromeres.
Mellor et al. (15) have proposed that CPI-CDEI-binding is
required for the centromere activity of CP1 but not to support
methionine prototrophy, implying that CP1 acts via different
was based on the analysis of a site-directed basic region cpfl
(cepl) mutant, YAG214, which was found to possess no
detectable CDEI-binding activity in vitro, but which conferred
methionine prototrophy and partially rescued centromere function
when expressed in yeast. This is the same phenotype we observe
with the NA162, NA137, and NA33 frame-shift alleles: strains
grow in the absence of methionine, show intermediate
chromosome loss rates, and yield crude extracts devoid of
detectable CDEI-binding activity. Our interpretation of this result
is simply that very low levels of CP1 activity are sufficient for
partial function and that less CP1 is required to maintain
methionine prototrophy than to maintain full centromere function.
We suggest that the Met+Chl phenotype of the YAG214
mutant could be explained similarly, i.e., the YAG214 gene
product has a low but nonzero binding affinity and provides
residual function in vivo.
CP1 is a relatively abundant protein (27, 35), and results here
suggest that the nuclear concentration of CP1 is, in fact, well
in excess of the minimum required for wild-type function (at least
with respect to the two phenotypes we analyze). First, the
LI-318SR allele in single copy is wild-type in function even
though its apparent CDEI binding affinity is reduced 9-fold.
Second, the N-terminal truncation/frame shift alleles, which
appear to be expressed at a very small fraction of wild-type levels,
still provide significant CPL function. Finally, the absence of
dominant negative effects in a wild-type CEPI background could
be interpreted to suggest excess CP1. A cellular surplus of CPl
would explain the previous finding that a centromeric CDEI
mutation which reduces binding 45-fold causes no apparent
phenotypic effect (27, 36).
Previous mutational analyses of CP1 have identified critical
functional domains. As for other members of this family, the
b-HLH domain is essential for DNA binding (3, 15, 32). Two
of the mutations studied here are located in this domain, and both
reduce CDEI-binding affinity by at least 500-fold. The R235H
point mutation changes a conserved arginine residue in the basic
region which has been shown to be responsible for specific
recognition of the inner dinucleotide of the consensus CANNTG
binding site motif (CACRTG in the case of CP1) (14, 33). The
LI-259 mutation disrupts the second helix of the HLH domain
and would be expected to affect CP1 dimerization (32). Dowell
et al. have reported that the C-terminal region of CP1 (spanning
codons 292-320) comprises a second dimerization domain that
is essential for DNA binding and CP1 function in vivo (34). The
significantly decreased DNA binding affinities of the CA302,
LI-301, LI-318PG, and LI-318SR proteins confirm the
importance of this domain for DNA binding; however, since the
CA302 allele lacks two thirds of these amino acids and still binds
DNA specifically, we conclude that the HLH domain of CP1
is sufficient to mediate dimerization. In addition to an effect on
DNA binding, the LI-318PG mutation appears to destabilize CP1
in vivo. This mutation inserts a proline into a region of CP1 which
is predicted to be ca-helical in structure (34).
While DNA binding appears to be necessary for CP1 function,
CDEI-binding per se is not sufficient. The TFEB protein has an
apparent CDEI binding affinity close to that of wild-type CP1,
is expressed at a comparable level, but is devoid of biological
function. Also, the inactivity of LI-301 cannot be explained solely
by its reduced affinity, since strains expressing LI-301 from a
multicopy vector contain wild-type levels of CDEI-binding
activity. Both TFEB and LI-301 gene products apparently enter
the nucleus and occupy CDEI sites, because both alleles exertmechanisms to carry out its multiple functions. This conclusion
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strong dominant negative effects on the ability ofPHO4 to activate
MET genes. Our working hypothesis is that CP1 acts primarily
to configure chromatin into a conformation which facilitates the
assembly of functional kinetochores and active transcription
complexes. CP1 is known to influence chromatin structure at both
gene promoter regions and centromeres (3), but it is not known
if the CP1-associated chromatin structures are established
independently by CP1 or require the participation of cofactors,
which could differ in each case. Since CDEI site occupation alone
appears to be insufficient to mediate CP1 function, CP1 must
contribute an additional activity. The protein domain conferring
the effector function is apparently located within the C-terminal
third of the protein and may be the target of the LI-301 mutation.
This functional domain might interact with histones or other
chromatin proteins to enhance (or inhibit) the assembly of higher
order structures.
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